News
-
What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease?
There is a lot of hustle and bustle in the scientific fields of thalassemia and sickle cell disease during the past few months, with many companies making remarkable progress in…
Read More » -
TIF Participates in EMA’s Annual Training Day 2020
TIF has participated in the Annual Training Day of the European Medicines Agency (EMA), held on 23 October 2020. TIF participants, Ms Lily Cannon (TIF Operations Manager) and Ms Eleni…
Read More » -
EU Approves Adakveo to Treat Vaso Occlusive Crises in Sickle Cell Disease Patients
The European Commission has approved Novartis’ Adakveo (crizanlizumab) as a preventive treatment for recurrent Vaso-Occlusive Crises (VOCs) in patients, 16 and older, with sickle cell disease (SCD). This approval follows a recommendation for conditional approval issued in July…
Read More » -
-
TIF Webinar Fridays Are Back With A New Session on “Heart Disease In Thalassaemia”
This Friday, 23 October 2020, at 15:00 EEST/13:00 BST, get ready to join Prof. Malcolm Walker and Dr. Dimitris Farmakis in our webinar on ”Heart Disease In Thalassaemia” for Patients/Parents,…
Read More » -
-
-
EdiGene Application of CRISPR/Cas 9 Gene-editing Therapy ET-01 For β-Thalassaemia Has Been Accepted For Review
Τhe Chinese biotechnology company EdiGene announced yesterday that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted for review the Company’s Investigational New Drug…
Read More » -
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed yesterday evening. The pharmaceutical giant was unclear if the patient…
Read More » -
TIF At The NORBS Online Regional Conference For Rare Diseases – 23 0ctober 2020
Supporting Serbia and other Eastern European countries in their efforts to upgrade holistic care services for patients with rare diseases, including thalassemia, TIF’s Executive Director, Dr Androulla Eleftheriou, participated on…
Read More »